A UK market access summit convened by IQVIA brought together pharma and NHS leaders to look at how working more closely – including more outcomes-based deals – could help UK life sciences through Brexit and beyond.
pharma market access
UK drug pricing: just how free is free pricing, these days?
‘Free’ pricing in the UK: the influence of NICE and NHS England
Should there be a different review of NICE as part of a successor PPRS?
NICE numbers: trends in recommendations should prompt a review of NICE
MINT countries: what the opportunities may be for pharma and healthcare.
New frontiers in pharma: is ‘MINT’ the next ‘BRIC’?